Sigyn Therapeutics Files 8-K: Material Agreement, Equity Sales, Officer Changes

TL;DR

Sigyn Therapeutics inked a material deal, sold equity, and shuffled execs. Big moves ahead.

AI Summary

Sigyn Therapeutics, Inc. announced on August 14, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in its board and officer composition, including the appointment of new officers and compensatory arrangements. The filing also covers other events and financial statements/exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and strategic direction.

Risk Assessment

Risk Level: medium — The filing details material agreements and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

• Sigyn Therapeutics, Inc. (company) — Registrant
• August 14, 2025 (date) — Date of report
• August 7, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $550,000 — terms of the Purchase Agreement, up to $550,000 in aggregate principal amount of one-ye
• $500,000 — ory notes (the "Notes") in exchange for $500,000. The Notes are convertible, at the opti
• $110,000 — es in the aggregate principal amount of $110,000 to Lambda Venture Partners, LLC, and re
• $100,000 — bda Venture Partners, LLC, and received $100,000 in proceeds, consistent with the Purcha

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex99-1.htm (EX-99.1) — 265KB
• 0001641172-25-024303.txt ( ) — 508KB
• sign-20250814.xsd (EX-101.SCH) — 3KB
• sign-20250814_lab.xml (EX-101.LAB) — 33KB
• sign-20250814_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

01

Item 1.01. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On August 8, 2025, Richa Nand and Michael Ryan notified Sigyn Therapeutics, Inc. (the "Company") of their decision to resign from the Company's Board of Directors, effective August 8, 2025. On August 7, 2025, Christopher Wetzel notified the Company of his decision to resign from the Board of Directors, effective August 7, 2025. The resignations were based on the Company's discontinuation of directors' and officers' liability insurance coverage, as further described below. The Company has provided Ms. Nand, Mr. Ryan and Mr. Wetzel with a copy of this Form 8-K and the disclosures made herein. Should the Company receive a letter from Ms. Nand, Mr. Ryan or Mr. Wetzel that does not agree with the disclosure made herein, the Company will file an amendment to this Form 8-K within two business days after the receipt of such letter. Item 8.01 Other Events. The Company's directors' and officers' liability insurance policy expired on August 4, 2025. The Company did not extend the policy and has not yet obtained replacement coverage. The Company is evaluating alternatives for securing such coverage in the future. The discontinuation of coverage was not related to any specific claim or proceeding against the Company or its directors or officers. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Title 99.1 Convertible Note Purchase Agreement 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: August 14, 2025 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO

View Full Filing

View this 8-K filing on SEC EDGAR